AMAG slides on FDA rejection of Feraheme label expansion
This article was originally published in Scrip
Executive Summary
Shares of AMAG Pharmaceuticals dropped more than 15% on 22 January on word the FDA had rejected the firm's supplemental new drug application (sNDA) to expand the labeling for the company's intravenous iron replacement product Feraheme (ferumoxytol).